Top View
- Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach
- Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in P53-Mutant Triple-Negative Breast Cancer Natalie A
- Deoxycytidine-Derivative, in Human Cancer Cells
- The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
- A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to Mtor Inhibitors
- Chronotherapeutics of Seliciclib
- Design of Novel BH3 Mimetics for the Treatment of Chronic Lymphocytic Leukemia
- N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
- Targeting the Cyclin-Dependent Kinases (CDK) 4/6 in Estrogen Receptor-Positive Breast Cancers Richard S
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
- Wo 2010/095940 A2
- Combined Venetoclax and Alvocidib in Acute Myeloid Leukemia
- The Anti-Inflammatory Effect of Seliciclib
- Innovative Medicines for Cancer and Other Proliferative Diseases Using Cell Cycle Biology
- Discovery and Development of Seliciclib. How Systems Biology
- Seliciclib (CYC202, R-Roscovitine)
- The Cyclin-Dependent Kinase Inhibitor SNS-032 Has Single Agent Activity in AML Cells and Is Highly Synergistic with Cytarabine
- Customs Tariff - Schedule Xxi - 1
- Event - Cyclacel Seeking Return on Investment During Crucial Period
- Inhibition of NF-Kb–Mediated Signaling by the Cyclin
- Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib)
- Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death Xiaoou Xu1, Shizuka Eshima1, Shinichiro Kato1,2, David E
- Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
- Prostate Cancer Cells Hyper-Activate CXCR6 Signaling by Cleaving CXCL16 to Overcome Effect of Docetaxel T
- Combination Motif Immune Stimulatory Oligonucleotides with Improved Activity
- Drug-Induced Reactivation of Apoptosis Abrogates HIV-1 Infection
- Cellular and Molecular Mechanisms of R/S-Roscovitine and Cdks
- Other Targeted Drugs in Melanoma
- Clicktozoomintothepdf
- Targeting the Rheumatoid Arthritis Synovial fibroblast Via Cyclin Dependent Kinase Inhibition an Early Phase Trial Stefan Siebert, MD, Phda , Arthur G
- The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinaciclib) Induces the Apoptosis of Osteosarcoma Cells Wei Fu1, Le Ma1, Baok
- Customs Tariff - Schedule Xxi - 1
- Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe
- CDK Inhibitors: a Promising New Class of Targeted Therapies
- Oncology Drugs in the Pipeline
- Compositions for Treating Breast Cancer
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
- Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
- The Cyclin-Dependent Kinase Inhibitor P57kip2 Is Epigenetically Regulated
- Graphical Abstract CG 18-2-MS
- Seliciclib and Sapacitabine
- Medicines & Vaccines in Development for Cancer
- Polo Like Kinase 2 Tumour Suppressor and Cancer Biomarker: New Perspectives on Drug Sensitivity/Resistance in Cancer Helen M
- Development of Cell-Cycle Inhibitors for Cancer Therapy
- Drug Targets and Resistance Mechanisms in Multiple Myeloma
- A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors
- Improved Tumor Control Through Circadian Clock Induction By
- Targeting CDK9 for the Treatment of Glioblastoma
- Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines
- Cyclin E Drives Human Keratinocyte Growth Into Differentiation
- WO 2016/025904 Al 18 February 2016 (18.02.2016) P O P C T
- Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury
- Cyclacel Pharmaceuticals, Inc. 2007 Annual Report Recent Cyclacel Milestones